An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer

References

• Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Search terms “PD-1” “PD-L1” combined; recruiting and enrolling studies. http://clinicaltrials.gov/ ( Accessed 27 Nov 2017)
   Google Scholar
• Schachter J, Ribas A, Long GV, Arane A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. 2017. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862. doi:10.1016/S0140-6736(17)31601-X.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey L, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. doi:10.1056/NEJMoa1504030.
   PubMedGoogle Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330. doi:10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al. 2017. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol JCO2017743062. doi:10.1200/JCO.2017.74.3062.
   PubMedGoogle Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, M.D., Vokes EE, Holgado E, et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. 2016. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497–1508. doi:10.1016/S1470-2045(16)30498-3.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMedGoogle Scholar
• Smyth MJ, Yagita H. 2016. McArthur GA: combination anti-CTLA-4 and anti-RANKL in metastatic melanoma. J Clin Oncol 34:e104–e106. doi:10.1200/JCO.2013.51.3572.
   PubMed Web of Science ®Google Scholar
• Bostwick AD, Salama AK, Hanks BA. 2015.Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 3:19.
   Google Scholar
• Angela Y, Tolk H, Oberndörfer F, et al.: Kombination von denosumab und checkpoin inhibitoren - eine retrospektive analyse von 10 patienten mit metastasierenden melanom und knochenmetastasen. Presented at the Deutscher Hautkrebskongress (German Skin Cancer Congress) - Arbeitsgemeinschaft Dermatologische Onkologie (ADO), Mainz, Germany, 2017
   Google Scholar
• Ahern E, Harjunpaa H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ. 2017. Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice. Clin Cancer Res 23:5789–5801. doi:10.1158/1078-0432.CCR-17-0606.
   PubMed Web of Science ®Google Scholar
• Ahern E, Harjunpaa H, O’Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ. 2018. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology. doi:10.1080/2162402X.2018.1431088.
   Web of Science ®Google Scholar
• Barth A, Wanek LA, Morton DL. 1995.Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193–201.
   PubMed Web of Science ®Google Scholar
• Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. 2017. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol 24:228–233. doi:10.3747/co.24.3496.
   PubMed Web of Science ®Google Scholar
• Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. 2013. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2:22–29. doi:10.1016/j.jbo.2012.12.004.
   PubMed Web of Science ®Google Scholar
• Tsuya A, Kurata T, Tamura K, Fukuoka M. 2007. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57:229–232. doi:10.1016/j.lungcan.2007.03.013.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, et al. 2016. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2980–2987. doi:10.1200/JCO.2016.66.9929.
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, M.D., McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar
• Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW. 2018. Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices. J Immunother 41:86–95.
   PubMed Web of Science ®Google Scholar
• Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, et al. 2018. Characteristics of real-world metastatic non-small cell lung cancer patients treated with nivolumab and pembrolizumab during the year following approval. Oncologist doi:10.1634/theoncologist.2017-0353.
   PubMed Web of Science ®Google Scholar
• Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. 2017. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol 13:1699–1710. doi:10.2217/fon-2017-0187.
   PubMed Web of Science ®Google Scholar
• Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H 2017. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci 108:1000–1006. doi:10.1111/cas.13225.
   PubMed Web of Science ®Google Scholar
• Tournoy KG, Thomeer M, Germonpre P, Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E, Schildermans R, Declercq I, et al. 2018. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer 115:49–55. doi:10.1016/j.lungcan.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Nakachi I, Naoki K, Satomi R, Nakamura M, Inoue T, Tateno H, Sakamaki F, Sayama K, Terashima T, et al. 2018. Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis. Clin Lung Cancer 19:e349–e358. doi:10.1016/j.cllc.2018.01.001.
   PubMed Web of Science ®Google Scholar
• Dudnik E, Moskovitz M, Wollner M, Zer A, Bar J, Agbarya A, Idan T, Shechtman Y, Amna MA, Peled N. 2016. Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): the real-life setting experience (181P). J Thorac Oncol 11:S57–S166. doi:10.1016/S1556-0864(16)30291-X.
   Web of Science ®Google Scholar
• Mohr P, Ascierto P, Arance A, Ascierto PA, Banos A, Kaskel P, Shinde R, Stevinson K. 2017. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. J Eur Acad Dermatol Venereol
   Web of Science ®Google Scholar
• Middleton MR, Dalle S, Claveau J, Mut P, Hallmeyer S, Plantin P, Highley M, Kotapati S, Kim T, Brokaw LJ, et al. 2016. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med 5:1436–1443. doi:10.1002/cam4.717.
   PubMed Web of Science ®Google Scholar
• Ahmad SS, Qian W, Ellis S, Mason E, Khattak M, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, et al. 2015. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 25:432–442. doi:10.1097/CMR.0000000000000185.
   PubMed Web of Science ®Google Scholar
• Gallagher PF, Stewart J, Carser JE, et al. 2017. Ipilimumab for advanced melanoma in the real world: the Northern Ireland experience (22P). ESMO immuno-oncology congress. Ann Oncol 28:xi6–xi29. doi:10.1093/annonc/mdx711/2017.
   Google Scholar
• Flynn AE, Day FL, Geyde CA, et al. ‘Real world’ pembrolizumab in metastatic melanoma (#226), Joint 2016 COSA and ANZBCTG Annual Scientific Meeting. Queensland, Australia, 2016
   Google Scholar
• Jansen Y, Rozeman EA, Foppen MG, Bastholt L, Schmidt H, Van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä SP, et al. 2017. Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression. J Clin Oncol 35:9539.
   Web of Science ®Google Scholar
• Dougall WC. 2012. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:326–335. doi:10.1158/1078-0432.CCR-10-2507.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, et al. 2012. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823–1829. doi:10.1097/JTO.0b013e31826aec2b.
   PubMed Web of Science ®Google Scholar
• Branstetter D RANK and RANK Ligand (RANKL) expression in primary human lung cancer (ID 870). Presented at the 15th World Conference on Lung Cancer, Sydney, Australia, 2013
   Google Scholar
• Rao S, Sigl V, Wimmer RA, Novatchkova M, Jais A, Wagner G, Handschuh S, Uribesalgo I, Hagelkruys A, Kozieradzki I, et al. 2017. RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Genes Dev 31:2099–2112. doi:10.1101/gad.304162.117.
   PubMed Web of Science ®Google Scholar
• Kupas V, Weishaupt C, Siepmann D, Kaserer ML, Eickelmann M, Metze D, Luger TA, Beissert S, Loser K. 2011. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131:944–955. doi:10.1038/jid.2010.377.
   PubMed Web of Science ®Google Scholar
• Liede A, Hernandez RK, Roth M, Calkins G, Larrabee K, Nicacio L. 2015. Validation of international classification of diseases coding for bone metastases in electronic health records using technology-enabled abstraction. Clin Epidemiol 7:441–448. doi:10.2147/CLEP.S92209.
   PubMed Web of Science ®Google Scholar
• Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175:2167–2173. doi:10.4049/jimmunol.175.4.2167.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu T-E, Badin F, et al. 2017. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426. doi:10.1056/NEJMoa1613493.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R1, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al.2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, et al. 2016. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600–1609. doi:10.1001/jama.2016.4059.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar